Skip to content

Trails Edge Capital Partners, LP

Follow

13F filer, CIK 2077247, ATLANTA, GA

Trails Edge Capital Partners, LP reported $695,902,449 across 38 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 48.72% of the portfolio.

Accepted , ingested 13F-HR 0002077247-26-000005

Period
2026-09-30
Reported value
$696M
Holdings
38
Top 10 weight
48.72%
New
9
Sold out
6

Part of the filer group Trails Edge Capital Partners, LP

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
OBXnew+2,495,660$34.3M
TNGXnew+1,100,000$27.4M
CLDXnew+765,000$24.8M
CTNMnew+1,693,694$22.7M
TYRAnew+1,000,000$21.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MIRMexited-223,312-$26.1M
TRAXreduced-700,000-$24.8M
INSMexited-230,331-$24.6M
SNDXexited-1,110,000-$24.3M
RVMDexited-115,750-$21.7M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0002077247-26-000005, largest first. % of portfolio is the value over $695,902,449, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,395,608 shares; 2026Q1: 1,319,362 shares; 2026Q2: 1,523,022 shares; 2026Q3: 1,149,240 shares 1,149,240$44.1M6.34%-373,782Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 512,000 shares; 2026Q3: 667,000 shares 667,000$40M5.75%+155,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,743,220 shares; 2026Q1: 1,743,220 shares; 2026Q2: 1,573,220 shares; 2026Q3: 1,573,220 shares 1,573,220$37.3M5.36%0Timeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,495,660 shares 2,495,660$34.3M4.92%newTimeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 682,597 shares; 2026Q1: 682,597 shares; 2026Q2: 1,063,234 shares; 2026Q3: 1,063,234 shares 1,063,234$32.2M4.63%0Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 1,302,917 shares; 2026Q2: 2,227,917 shares; 2026Q3: 2,227,917 shares 2,227,917$31.9M4.58%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 852,013 shares; 2026Q2: 2,001,282 shares; 2026Q3: 2,500,000 shares 2,500,000$31.4M4.52%+498,718Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 300,000 shares; 2026Q2: 288,089 shares; 2026Q3: 470,000 shares 470,000$31M4.45%+181,911Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,514,000 shares; 2026Q3: 814,000 shares 814,000$28.8M4.15%-700,000Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 125,000 shares; 2026Q2: 515,335 shares; 2026Q3: 941,689 shares 941,689$28M4.02%+426,3542026-11-09, 13G: 1,385,878 shares, 5.4% of the class, 13G filed 2026-11-17 Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,100,000 shares 1,100,000$27.4M3.94%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 785,000 shares; 2026Q1: 782,787 shares; 2026Q2: 714,885 shares; 2026Q3: 964,885 shares 964,885$26.8M3.86%+250,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 765,000 shares 765,000$24.8M3.56%newTimeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 891,881 shares; 2026Q3: 1,500,000 shares 1,500,000$23M3.3%+608,1192026-10-22, 13G: 2,803,761 shares, 5.2% of the class, 13G filed 2026-10-29 Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,693,694 shares 1,693,694$22.7M3.27%newTimeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 700,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,000,000 shares 1,000,000$21.9M3.14%newTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 750,000 shares; 2026Q3: 1,680,000 shares 1,680,000$19.7M2.82%+930,000Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 6,178,124 shares; 2026Q1: 8,057,345 shares; 2026Q2: 9,051,318 shares; 2026Q3: 9,110,112 shares 9,110,112$18.7M2.69%+58,794Timeline
INBXINHIBRX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 170,000 shares 170,000$17M2.44%newTimeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 597,092 shares; 2026Q1: 440,000 shares; 2026Q2: 440,000 shares; 2026Q3: 400,000 shares 400,000$14.9M2.14%-40,000Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,983,986 shares; 2026Q1: 1,939,563 shares; 2026Q2: 1,932,937 shares; 2026Q3: 3,625,576 shares 3,625,576$14.6M2.1%+1,692,639Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,660,000 shares; 2026Q3: 4,230,000 shares 4,230,000$12.1M1.74%+1,570,000Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 2,743,658 shares; 2026Q3: 2,411,657 shares 2,411,657$11.7M1.68%-332,001Timeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 984,786 shares; 2026Q3: 942,953 shares 942,953$10.8M1.55%-41,833Timeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 85,496 shares; 2026Q2: 139,445 shares; 2026Q3: 139,445 shares 139,445$10.4M1.49%02026-10-20, 13G: 166,473 shares, 5.1% of the class, 13G filed 2026-10-27 Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 2,657,997 shares; 2026Q1: 2,657,997 shares; 2026Q2: 2,657,997 shares; 2026Q3: 2,657,997 shares 2,657,997$9.81M1.41%0Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,428,440 shares 1,428,440$9.07M1.3%newTimeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,443,333 shares; 2026Q3: 1,443,333 shares 1,443,333$9.06M1.3%0Timeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares; 2026Q3: 822,500 shares 822,500$8.91M1.28%+322,500Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 2,571,478 shares; 2026Q1: 2,571,478 shares; 2026Q2: 2,571,478 shares; 2026Q3: 2,571,478 shares 2,571,478$7.46M1.07%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 2,449,993 shares; 2026Q2: 4,134,969 shares; 2026Q3: 4,134,969 shares 4,134,969$7.07M1.02%0Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 557,103 shares; 2026Q2: 557,103 shares; 2026Q3: 557,103 shares 557,103$6.04M0.87%0Timeline
RACDRESEARCH ALLIANCE CORP IVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$6M0.86%newTimeline
IMAIMAGENEBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 282,004 shares; 2026Q3: 1,094,045 shares 1,094,045$5.01M0.72%+812,041Timeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 1,419,000 shares; 2026Q2: 1,419,000 shares; 2026Q3: 1,419,000 shares 1,419,000$4.75M0.68%0Timeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 250,000 shares 250,000$3.13M0.45%newTimeline
VTVTVTV THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 231,000 shares; 2026Q1: 139,578 shares; 2026Q2: 85,192 shares; 2026Q3: 76,989 shares 76,989$2.37M0.34%-8,203Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,438,456 shares; 2026Q3: 619,557 shares 619,557$1.69M0.24%-818,899Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
MIRMMIRUM PHARMACEUTICALS INC223,312$26.1Mshares
INSMINSMED INC230,331$24.6Mshares
SNDXSYNDAX PHARMACEUTICALS INC1,110,000$24.3Mshares
RVMDREVOLUTION MEDICINES INC115,750$21.7Mshares
INCYINCYTE CORP155,000$17.6Mshares
FBRXFORTE BIOSCIENCES INC273,181$5.81Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002077247-26-000005 base2026-11-16